Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Study Summary

The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).

Conditions

Prostate Cancer High-risk Biochemical Recurrence High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer Non-metastatic Castration-sensitive Prostate Cancer

Interventions / Drugs

Xaluritamig

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment50 participants

Primary Completion—

Lead SponsorAmgen

Data Retrieved2026-04-13 18:29:34.157729+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.